Vaginal versus oral Misoprostol for second–trimester pregnancy termination

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103281760N11

Enrollment

Registered

2011-11-01

Start date

2010-03-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second trimester termination of pregnancy. Termination of pregnancy, fetus and newborn

Interventions

Intervention 1: First group: 600 µcg vaginal Misoprostol as initial dose, and then 400 micrograms of oral misoprostol every four hours up to receive three doses. Intervention 2: Second group: 600 µcg

Treatment - Drugs

First group: 600 µcg vaginal Misoprostol as initial dose, and then 400 micrograms of oral misoprostol every four hours up to receive three doses.

Second group: 600 µcg vaginal Misoprostol as initial dose, and then 400 micrograms of vaginal misoprostol every four hours up to receive three doses.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: Pregnant women Hospitalized in the second–trimester (24-14 weeks gestation) for abortion with single pregnancy, parity conditions 1 to 3, without pain, uterine infection and dilatation are less than 2cm. Exclusion criteria: Multiple pregnancy, Chorioamnionits previous uterus incision, parity over 3, patients with asthma, liver, kidney and heart disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Abortion. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.	—

Secondary

Measure	Time frame
Number of tablets consumed. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.;Possible Complications. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.;Amount of bleeding. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.;The need for curettage. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.	—

Measure

Time frame

Number of tablets consumed. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.;Possible Complications. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.;Amount of bleeding. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.;The need for curettage. Timepoint: The start of the intervention up to 24 hours. Method of measurement: Clinical examinations.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNargess Gholizadeh Pasha

Fatemehzahra Fertility & reproductive Health Research Center

ngh_pa@yahoo.com, zahra@mubabol.ac.ir+98 11 1227 4881

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026